Glutaminergic Transmission in Autism : Molecular Imaging Exploration

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02719951

Acronym

TANGAU

Enrollment

Registered

2016-03-25

Start date

2016-04-30

Completion date

2019-05-31

Last updated

2025-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism, Fragile-X Syndrome (FXS), Healthy Volunteers

Keywords

autism, fragile X syndrome (FXS), PET (Positron Emission Tomography), glutamate

Brief summary

Glutamatergic transmission exploration using PET (Positron Emission Tomography) imaging in autism compared to Fragile-X Syndrome ( FXS) and Healthy Volunteers

Interventions

DRUG[18F]FPEB PET imaging

PET exam

OTHERBiological samples

blood sample and urine sample

OTHERMRI

MRI exam

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Male * Between 18 years-old and 45 years-old * Informed, written consent obtained from patient or his representant * Subject with an affiliation to French social security * For autistic patient : patient with diagnosis of ASD (Autistic Spectrum Disorders) following DSM-IV or DSM-5 criteria with recommended tools (ADI-R and/or ADOS) * For FXS patient : diagnosis of FXS and confirmation of total mutation of FMR1

Exclusion criteria

* Contraindications to MRI * Excessive use of alcohol or drug, or addiction to alcohol or drug during last 6 months * Any unstable or uncontrolled disease, clinically significant * Participation to an other experimental protocol with drug or irradiant exam * Person under exclusion period because of previous participation to an other experimental protocol * Person under temporary guardianship * Forbidden treatments : any psychotropic treatment for 4 last weeks before PET exam and changing durably glutaminergic transmission directly or undirectly * For healthy subjects : adult under guardianship, medical history of central nervous system disease, medical history of attention deficit hyperactivity disorder, past or present psychiatric or neurologic disorder (MINI DSM-IV)

Design outcomes

Primary

Measure	Time frame
cerebral glutaminergic activity assessed by binding potential of [18F]FPEB	An average of 3 years

Secondary

Measure	Time frame
distribution volume of [18F]FPEB	An average of 3 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026